Table 3. Genomic alteration rates of THOR referring to TCGA/GENIE/GENIE metastasis patients.
| Gene | Altered | Tested | THOR Alteration Rate (n = 415) | TCGA Alternation Rate (n = 507) | GENIE Alternation Rate (n = 6529) | GENIE Metastasis Alternation Rate (n = 2697) |
|---|---|---|---|---|---|---|
| EGFR | 207 | 415 | 50% | 16% | 25% | 25% |
| TP53 | 140 | 283 | 50% | 52% | 47% | 55% |
| LRP1B | 63 | 228 | 28% | 37% | 22% | 23% |
| KRAS | 97 | 352 | 28% | 33% | 34% | 30% |
| ARID1B | 36 | 191 | 19% | 7% | 5% | 6% |
| MLL3 | 35 | 190 | 18% | 15% | 6% | 7% |
| SPTA1 | 35 | 190 | 18% | 31% | 10% | 13% |
| ARID1A | 41 | 232 | 18% | 7% | 8% | 9% |
| FAT1 | 29 | 191 | 15% | 12% | 9% | 10% |
| BRCA2 | 33 | 234 | 14% | 6% | 5% | 6% |
| STK11 | 39 | 278 | 14% | 16% | 14% | 15% |
| MLL2 | 31 | 228 | 14% | 8% | 9% | 10% |
| MLL | 30 | 228 | 13% | 7% | 5% | 5% |
| GPR124 | 29 | 228 | 13% | 7% | 5% | 6% |
| ATM | 35 | 276 | 13% | 10% | 8% | 9% |
| KEAP1 | 27 | 228 | 12% | 20% | 15% | 17% |
| MET | 33 | 287 | 12% | 7% | 5% | 7% |
| NKX2-1 | 26 | 228 | 11% | 14% | 8% | 9% |
| ALK | 42 | 377 | 11% | 7% | 5% | 6% |
| SETD2 | 25 | 228 | 11% | 7% | 7% | 7% |
| NFKBIA | 24 | 228 | 11% | 12% | 4% | 6% |
| SMARCA4 | 24 | 228 | 11% | 10% | 9% | 11% |
| APC | 28 | 274 | 10% | 6% | 5% | 6% |
| SDHA | 19 | 191 | 10% | 14% | 4% | 6% |
| NOTCH1 | 27 | 276 | 10% | 5% | 3% | 4% |
Genomic alteration data were collected for 415 THOR lung adenocarcinoma patients, 507 TCGA Lung Adenocarcinoma patients (study id = luad_tcga_pan_can_atlas_2018), 6529 GENIE Lung Adenocarcinoma patients (GENIE Cohort v5.0-public, cancer type detailed = lung adenocarcinoma), and 2697 GENIE metastasis lung adenocarcinoma patients (GENIE Cohort v5.0-public, cancer type detailed = lung adenocarcinoma, sample type = Metastasis).